IgM ELISA follow-up of spiramycin treatment for toxoplasmosis: should the drug be prescribed in India?
Singh
S
S
D000328:Adult; D000818:Animals; D000913:Antibodies, Protozoan / Q000032:analysis*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007075:Immunoglobulin M / Q000032:analysis*; D007231:Infant, Newborn; D011247:Pregnancy; D011739:Pyrimethamine / Q000627:therapeutic use; D015572:Spiramycin / Q000627:therapeutic use*; D013411:Sulfadiazine / Q000627:therapeutic use; D014122:Toxoplasma / Q000276:immunology*; D014125:Toxoplasmosis, Congenital / Q000517:prevention & control*
D000913:Antibodies, Protozoan; D007075:Immunoglobulin M; D013411:Sulfadiazine; D015572:Spiramycin; D011739:Pyrimethamine